報價延遲最少15分鐘:2025/05/13 12:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.74/-0.20
|
|
企業價值
10.86M
|
| 資產負債 |
|
每股賬面淨值
-0.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
183.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 12:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions. |